In recent years, clinical studies have found that tumor cells are highly expressed by immune checkpoint proteins to reduce the intensity of the body’s innate and adaptive immune response while promoting the “Immune Escape” of tumor cells. Therefore, therapeutic monoclonal antibodies that target immune checkpoint proteins have become the latest strategy for cancer treatment. Examples include anti-CTLA-4 antibody (Iplimumab), anti-PD-1 monoclonal antibody (Nivolumab, Pembrolizumab), and anti-PD-L1 monoclonal antibody (Avelumab, Atezolizumab, Durvalumab, etc.).
Synbio Technologies supplies most of the popular immune checkpoint proteins, including CTLA-4, PD-1, PD-L1, CD47, GITR, TIM-3/TIM1, etc.
*If you don’t find your desired recombinant protein products in the list, please contact email@example.com